Overview of Clomiphene Citrate Use in Male Hypogonadism and Infertility

Clomiphene Citrate (CC) has been widely used in medicine since the 1970s, primarily as a Selective Estrogen Receptor Modulator (SERM) for female ovulation induction. However, its off-label use in men has gained traction, particularly for the treatment of hypogonadotropic hypogonadism and idiopathic infertility. CC’s mechanism of action, which increases gonadotropin-releasing hormone (GnRH) secretion and subsequently elevates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, offers a unique advantage by preserving the hypothalamic-pituitary-gonadal axis and maintaining fertility. This article presents evidence supporting CC’s efficacy and safety in these contexts, summarizing data from systematic reviews, meta-analyses, and retrospective studies. In hypogonadotropic men, CC has been shown to significantly improve total and free testosterone levels, gonadotropin concentrations, and hypogonadism symptoms, while avoiding common complications of testosterone replacement therapy (TRT), such as secondary polycythemia. CC also demonstrated favorable outcomes in seminal parameters, including sperm concentration and motility, as well as improved pregnancy rates in idiopathic infertility cases. Adverse effects reported with CC use include reduced energy, mood instability, and occasional visual disturbances, most of which are mild and reversible. Long-term safety data are reassuring, with rare severe adverse events such as thrombotic complications. Studies comparing CC to TRT indicate a lower risk of hematological and prostate-related complications, underscoring its safety profile. While the evidence supports CC as a viable alternative or adjunct to TRT in specific patient populations, further research is needed to refine treatment protocols, assess long-term outcomes, and explore biofunctional sperm parameters. Overall, CC represents a promising, cost-effective therapeutic option for addressing male hypogonadism and infertility, with its integration into clinical practice guided by careful patient selection and ongoing monitoring.

Authors

Institutions

Publication Details

Journal
Asian Journal of Medicine and Health
Published
2024-12-28
DOI
https://doi.org/10.9734/ajmah/2024/v22i121153
Citations
2
Primary Topic
Hormonal and reproductive studies
Type
article
Field-Weighted Citation Impact
0.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Overview of Clomiphene Citrate Use in Male Hypogonadism and Infertility

Lucas Caseri Câmara
2 citations
Asian Journal of Medicine and Health
Hormonal and reproductive studies
0.72
article

Overview of Clomiphene Citrate Use in Male Hypogonadism and Infertility

Lucas Caseri Câmara
article en
2 citations

Abstract

Clomiphene Citrate (CC) has been widely used in medicine since the 1970s, primarily as a Selective Estrogen Receptor Modulator (SERM) for female ovulation induction. However, its off-label use in men has gained traction, particularly for the treatment of hypogonadotropic hypogonadism and idiopathic infertility. CC’s mechanism of action, which increases gonadotropin-releasing hormone (GnRH) secretion and subsequently elevates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, offers a unique advantage by preserving the hypothalamic-pituitary-gonadal axis and maintaining fertility. This article presents evidence supporting CC’s efficacy and safety in these contexts, summarizing data from systematic reviews, meta-analyses, and retrospective studies. In hypogonadotropic men, CC has been shown to significantly improve total and free testosterone levels, gonadotropin concentrations, and hypogonadism symptoms, while avoiding common complications of testosterone replacement therapy (TRT), such as secondary polycythemia. CC also demonstrated favorable outcomes in seminal parameters, including sperm concentration and motility, as well as improved pregnancy rates in idiopathic infertility cases. Adverse effects reported with CC use include reduced energy, mood instability, and occasional visual disturbances, most of which are mild and reversible. Long-term safety data are reassuring, with rare severe adverse events such as thrombotic complications. Studies comparing CC to TRT indicate a lower risk of hematological and prostate-related complications, underscoring its safety profile. While the evidence supports CC as a viable alternative or adjunct to TRT in specific patient populations, further research is needed to refine treatment protocols, assess long-term outcomes, and explore biofunctional sperm parameters. Overall, CC represents a promising, cost-effective therapeutic option for addressing male hypogonadism and infertility, with its integration into clinical practice guided by careful patient selection and ongoing monitoring.

Asian Journal of Medicine and HealthVol. 22(12)
Governo do Estado de São Paulo (BR)
Good health and well-being
Openalex Percentile: Top 23%
Hormonal and reproductive studies
0.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.